




Idorsia Company Profile

Headquartered in Switzerland – a biotech-hub of Europe – Idorsia is a high-potential biopharmaceutical company, specialized in the discovery, development, and commercialization of innovative small molecules, with the aim of transforming the horizon of therapeutic options.

We may be young, but we have a 20-year heritage of drug discovery, a broad portfolio of innovative drugs in the pipeline, an experienced team of over 800 professionals covering all disciplines from bench to bedside, and commercial operations in Europe and North America – the ideal constellation for bringing innovative medicines to patients.

- Company Profile
- > Financial overview 
- Company strategy
- Innovation portfolio
- Partnerships
- Company milestones

Financial overview	Nine Months			
	US GAAP		Non-GAAP*	
in CHF millions, except EPS (CHF) and number of shares (millions)	2023	2022	2023	2022
Net revenues	131	43	131	43
Operating expenses	(275)	(653)	(517)	(621)
Operating income (loss)	(144)	(610)	(386)	(577)
Net income (loss)	(181)	(635)	(420)	(597)
Basic EPS	(1.02)	(3.58)	(2.36)	(3.36)
Basic weighted average number of shares	178.2	177.4	178.2	177.4
Diluted EPS	(1.02)	(3.58)	(2.36)	(3.36)
Diluted weighted average number of shares	178.2	177.4	178.2	177.4

The full financial statements can be found in the Financial Report available on our corporate website.

* Idorsia measures, reports and issues guidance on non-GAAP operating performance. Idorsia believes that these non-GAAP financial measurements more accurately reflect the underlying business performance and therefore provide useful supplementary information to investors. These non-GAAP measures are reported in addition to, not as a substitute for, US GAAP financial performance.

Share Information

Idorsia was incorporated in March 2017 and listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017.

Idorsia Ltd is part of the following indices: SPI, SPIEX, SPI ESG, SXSLI, SXI Life Sciences, SXI Bio+Medtech, and SSIRT.

Idorsia is traded under the following symbols:
Reuters IDIA.S / Bloomberg IDIA:SW.

Company Strategy

We will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core. We have identified five key strategic priorities to ensure the company's success going forward.

Advance late-stage pipeline

We believe that our development compounds have the potential to significantly change treatment in their target diseases, resulting in medicines with substantial commercial potential.

Successfully launch our new products

In order to successfully bring our pioneering therapies to patients and to maximize the value of our innovations, we will continue to build and strengthen our global commercial organization.

Bring Idorsia to sustainable profitability

We are building Idorsia with a long-term focus and ambitious aspirations. By advancing our development pipeline and successfully launching our first products, we aim to bring Idorsia to sustainable profitability as soon as possible.

Fuel our pipeline with new discoveries

While launching our first marketed products and developing our late-stage clinical pipeline to bring our innovative therapies to patients, we also continue to discover new compounds.

Utilize state-of-the-art technologies to drive innovation

As we wish to remain at the cutting edge of science, it is vital that we consider innovative approaches and utilize state-of-the-art technologies at each stage of the process, from bench to bedside.

Company Profile

Financial overview

> Company strategy

[Innovation portfolio](#)

Partnerships

Company milestones

Innovation portfolio

Idorsia-led

Compound	Target indication	Mechanism of action						Status
			P1	P2	P3	R	C	
QUVIVIQ™ (daridorexant)	Insomnia	Dual orexin receptor antagonist	■	■	■	■	■	Commercially available as QUVIVIQ in the US, Germany, Italy, Switzerland, Spain, UK, Canada, and Austria; approved throughout the EU
Aprocitentan	Uncontrolled hypertension	Dual endothelin receptor antagonist	■	■	■	■	□	NDA under review in the US, MAA under review in the EU
Lucerastat	Fabry disease	Glucosylceramide synthase inhibitor	■	■	■	□	□	Phase 3 primary endpoint not met; open label extension study ongoing
Daridorexant	Pediatric insomnia	Dual orexin receptor antagonist	■	■	□	□	□	Phase 2 in pediatric insomnia ongoing
ACT-1004-1239	Demyelinating diseases inc. MS	ACKR3 / CXCR7 antagonist	■	■	□	□	□	Phase 2 in preparation
Sinbaglustat	Rare lysosomal storage disorders	GBA2/GCS inhibitor	■	□	□	□	□	Phase 1 complete
ACT-777991	Recent-onset Type 1 diabetes	CXCR3 antagonist	■	□	□	□	□	Phase 1 complete
ACT-1014-6470	Immune-mediated disorders	C5aR1 antagonist	■	□	□	□	□	Phase 1
IDOR-1117-2520	Immune-mediated disorders	Undisclosed	■	□	□	□	□	Phase 1 ongoing
IDOR-1134-2831	<i>Clostridium difficile</i> infection	Synthetic glycan vaccine	■	□	□	□	□	Phase 1 in preparation

P1: Phase 1, P2: Phase 2, P3: Phase 3, R: Registration, C: Commercially available

Company Profile

Financial overview

Company strategy

> Innovation portfolio

Partnerships

Company milestones

Innovation portfolio

Partner-led

Compound	Target indication	Mechanism of action	Partner Terms	Status					
				P1	P2	P3	R	C	
Daridorexant	Insomnia	Dual orexin receptor antagonist	Sosei Heptares License to develop and commercialize for Asia Pacific (ex-China)	■	■	■	■	□	NDA submitted in Japan
Daridorexant	Insomnia	Dual orexin receptor antagonist	Simcere License to develop and commercialize for Greater China region	■	■	■	□	□	Phase 3 ongoing
Selatogrel*	Acute myocardial infarction	P2Y ₁₂ inhibitor	Viatriis Worldwide development and commercialization rights.	■	■	■	□	□	Phase 3 "SOS-AMI" program ongoing
Cenerimod*	Systemic lupus erythematosus	S1P ₁ receptor modulator	Viatriis Worldwide development and commercialization rights (excluding Japan, South Korea and certain countries in the Asia-Pacific region).	■	■	■	□	□	Phase 3 "OPUS" program ongoing
Daridorexant	Posttraumatic stress disorder (PTSD)	Dual orexin receptor antagonist	US Department of Defense (DOD) Idorsia supports a clinical study sponsored by the US DOD to develop new therapies to treat PTSD.	■	■	□	□	□	Phase 2
ACT-709478/ NBI-827104	Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep (CSCW)	T-type calcium channel blocker	Neurocrine Biosciences Global license to develop and commercialize	■	■	□	□	□	Phase 2

P1: Phase 1, P2: Phase 2, P3: Phase 3, R: Registration, C: Commercially available

* The company expects to close the transaction with Viatriis by the end of March, subject to customary closing conditions

Company Profile

Financial overview

Company strategy

> Innovation portfolio

Partnerships

Company milestones

Partnerships

Halozyme

In 2019, Idorsia entered into a global agreement with Halozyme to develop a novel drug-device product combining selatogrel – Idorsia’s potent, fast-acting, reversible and highly selective P2Y₁₂ inhibitor – with Halozyme’s subcutaneous QuickShot® auto-injector. In 2021, Idorsia initiated the Phase 3 study SOS-AMI with the selatogrel drug-device for the treatment of suspected acute myocardial infarction. www.halozyme.com

Mochida

In 2019, Idorsia and Mochida Pharmaceutical entered into an exclusive license agreement for the supply, co-development and co-marketing of Idorsia’s daridorexant for insomnia and related disorders in Japan. www.mochida.co.jp

Neurocrine Biosciences

In 2020, Idorsia entered into a global license agreement with Neurocrine Biosciences for the development and commercialization of ACT-709478 (NBI-827104), Idorsia’s novel T-type calcium channel blocker. ACT-709478 is investigated in a Phase 2 open label extension (OLE) study for the treatment of pediatric patients with Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep (CSCW), a rare form of pediatric epilepsy. While the blinded-study did not meet the primary endpoint, ACT-709478 was generally well tolerated and Neurocrine continues to analyze the totality of data coming from the OLE study to determine next steps. www.neurocrine.com

Santhera

In 2020, Idorsia’s license, collaborative development and commercialization agreement with ReveraGen BioPharma in respect of vamorolone was transferred in its entirety to Santhera Pharmaceuticals, with the latter replacing Idorsia as a party to the agreement. Idorsia will be entitled to development and sales milestones, as well as low single-digit percentage payments on net sales of vamorolone. www.santhera.com

Syneos Health

In 2020, Idorsia and Syneos Health entered into an innovative commercial partnership to build the salesforce for the US launch of QUVIVIQ (daridorexant). In January 2022, Idorsia expanded this commercialization partnership to support the launch of QUVIVIQ and effectively reach the primary care market in Europe and Canada. www.syneoshealth.com

Simcere

In 2022, Idorsia and Simcere entered into an exclusive licensing agreement for Idorsia’s daridorexant in China. Under the agreement, Simcere has an exclusive right to develop and commercialize daridorexant in the Greater China region. en.simcere.com

Sosei Heptares

In 2023, Idorsia and Sosei Heptares entered into a co-exclusive license agreement for daridorexant in the Asia Pacific (ex-China) region*. In addition, Idorsia granted an option for Sosei Heptares to license cenerimod and lucerastat for the development and commercialization, and a right of first negotiation and right of first refusal on certain other pipeline assets in the region. www.soseiheptares.com

* Australia, Brunei, Cambodia, Indonesia, Japan, Laos, Malaysia, Myanmar, New Zealand, Philippines, Singapore, South Korea, Thailand, Taiwan, and Vietnam

Viatrix*

In 2024, Idorsia entered into a global development and commercialization agreement with Viatrix for selatogrel and cenerimod. A joint development committee will oversee the development of the ongoing Phase 3 programs for selatogrel (“SOS-AMI”) and cenerimod (“OPUS”) through regulatory approval. Viatrix has worldwide commercialization rights for both selatogrel and cenerimod (excluding, for cenerimod only, Japan, South Korea and certain countries in the Asia-Pacific region).

*The company expects to close the transaction by the end of March, subject to customary closing conditions, but no additional regulatory or shareholder approvals are required.

Company Profile

Financial overview

Company strategy

[Innovation portfolio](#)

> Partnerships

Company milestones

Company milestones

2024

March Global development and commercialization agreement with Viatrix for selatogrel and cenerimod

February QUVIVIQ (daridorexant) launched in Austria

2023

November QUVIVIQ (daridorexant) launched in Canada

October QUVIVIQ (daridorexant) launched in the UK

September QUVIVIQ (daridorexant) launched in Spain

June QUVIVIQ (daridorexant) launched in Switzerland

January MAA for apocritentan submitted to the EMA for the treatment of patients with resistant hypertension

2022

December NDA for apocritentan submitted to the US FDA for the treatment of patients with difficult-to-control hypertension

December OPUS Phase 3 program to investigate cenerimod for the treatment of patients with systemic lupus erythematosus initiated

November QUVIVIQ (daridorexant) launched in Germany and Italy

November The Lancet and American Heart Association (AHA) late-breaking science session reports significant and sustained effect of apocritentan on lowering blood pressure for patients with resistant hypertension

May Europe's first dual orexin receptor antagonist – QUVIVIQ (daridorexant) – granted approval to improve both nighttime symptoms and daytime functioning in adults with chronic insomnia disorder

May QUVIVIQ (daridorexant) 25 mg and 50 mg launched in the US for the treatment of adults with insomnia

January The Lancet Neurology reports impact of daridorexant on both nighttime symptoms and daytime functioning in adults with insomnia

Company Profile

Financial overview

Company strategy

[Innovation portfolio](#)

Partnerships

> **Company milestones**

2021

December Idorsia to further characterize lucerastat for Fabry disease by continuing the open-label extension of the Phase 3 MODIFY study

September Five Idorsia affiliates in key European markets (France, Germany, Italy, Spain, UK) established

June Initiation of Phase 3 registration study with selatogrel for the treatment of acute myocardial infarction

2020

July Establishment of Idorsia Pharmaceuticals US Inc. to perform commercial operations

May Global license agreement with Neurocrine Biosciences for the development and commercialization of ACT-709478

2019

November Collaboration Agreement with Halozyme for the development of a novel self-administered drug-device product for selatogrel

2017

June Idorsia opens its doors and is listed on SIX Swiss Stock Exchange

Company Profile

Financial overview

Company strategy

Innovation portfolio

Partnerships

> Company milestones

Idorsia is an independent biopharmaceutical company based on science and innovation. The company is specialized in the discovery, development, and commercialization of innovative small molecules, with the aim of transforming the horizon of therapeutic options. It is headquartered in Allschwil/Basel, Switzerland and is quoted on the SIX Swiss Exchange (tickersymbol: IDIA). All trademarks are legally protected by their respective owners.

Disclaimer This fact sheet has the sole purpose to provide members of the public with general information about the activities of Idorsia. The forward-looking statements in this fact sheet are based on current expectations and belief of company management, which are subject to numerous risks and uncertainties.

Idorsia Pharmaceuticals Ltd
Hegenheimermattweg 91
4123 Allschwil
Switzerland

investor.relations@idorsia.com
Phone +41 58 844 10 10
www.idorsia.com

